Carna Biosciences, Inc.
docirbrutinib (AS-1763) Development-Accelerating Stock Option Plan with Exercise Price Adjustment Clause – Monthly Exercise Status
Disclosure of the July 2026 monthly exercise status for the docirbrutinib (AS-1763) development-accelerating stock option. Shares issued: 40,000 shares; rights exercised: 400 (0.51% of issued shares). Unexercised rights at month-end: 7,570,300 shares. Exercise restriction ratio: 0.20%.
Key Figures
- Issued shares: 40,000 shares
- Number of stock options exercised: 400 rights
- Exercise rate against issued shares: 0.51%
AI要約
Overview
Curna Bioventures (カルナバイオサイエンス) discloses the July 2026 monthly exercise status for the docirbrutinib (AS-1763) stock option. Issued shares: 40,000; exercised rights: 400 (0.51% of issued shares); unexercised rights at month-end: 7,570,300. Exercise restriction ratio is 0.20%, indicating limited exercise in the target month.
Outlook & Impact
Exercise activity for stock options is limited, and dilution impact is expected to be small. Reference to related information from past disclosures is recommended, and additional disclosures may be considered depending on future exercise status.
カルナバイオサイエンス株式会社
Company overview · Stock price · Financial data · All IR
